Axogen (AXGN) Q2 FY26 earnings call: guidance and Q&A

Despite strong Breast growth, Q2 revenue growth decelerated from Q1. Can you provide more detail on the growth of other markets (Extremities, OMF & Head and Neck) for Q2 specifically?

Management stated they would not break out other segments individually but confirmed that Extremities and OMF & Head and Neck are growing consistent with prior comments and 'handsomely' on their respective bases.

“We're not going to break out the other segments as we are now Breast going forward. However, the other markets are growing consistent with prior comments. So relatively different bases, Extremities being the largest; OMF, Head and Neck being smaller; but all the markets are growing handsomely.”

asked by Michael Sarcone · answered by Michael Dale

What are the key assumptions behind the raised full-year guidance for H2, particularly regarding end markets and sales cadence?

The most significant factor is the successful investment in sales footprint coverage, which has shown high double-digit returns. Patient and surgeon awareness, especially in planned procedures like Breast, is also a growing driver. The company plans to aggressively expand its sales force within profitability constraints.

“The most significant factor if we had to pull one out that we now have enough time to look back upon is the investments in sales footprint coverage. So for all markets, those individual investments have been very rewarding. So very high double digits.”

asked by Michael Sarcone · answered by Michael Dale

Is there cause for concern regarding the delay in Aetna's policy update, given historical timelines?

Management is disappointed by the delay but views it optimistically, suggesting Aetna is taking time to 'get it right' rather than just rubber-stamping. They are hopeful for a favorable decision.

“We know they're looking at it and I would -- I try to view it through the optimistic lens, which is sometimes these medical policies can just get rubber stamped. Hey, this is the annual update, we're just going to pass it through and approve it. And the fact that they're taking time I think means they want to get it right. So we're hopeful.”

asked by Michael Sarcone · answered by Rick Ditto

Why is Breast, a higher ASP opportunity, driving lower margins? Can you elaborate on pricing and manufacturing initiatives and when their impact will be seen?

The lower margin is due to product mix, specifically the faster-than-expected growth of Breast business which uses higher-cost, longer Avance grafts. The pricing model for these grafts is not linear with cost. Management plans pricing actions and production efficiency initiatives, but these will not impact 2026 results. They still target a 75% long-term gross margin.

“But the gross margin plan assumed a relative constant in terms of the product mix between these. That's gotten ahead of us. It's driven by good news, i.e., breast adoption is going faster than we originally planned and assumed. But the result is that product mix reflects a higher relative cost and specifically for costing so our cost per millimeter is linear. What is not linear is our actual pricing model.”

asked by Gursimran Kaur · answered by Michael Dale

The guidance raise doesn't assume new payer wins. How much of the existing commercial reimbursement wins have been built into the back-half guidance, and can you quantify their impact?

Existing payer wins reduce sales cycles and overcome objections, but the magnitude is difficult to quantify. These events are not 'light switches' and take 6 months minimum to fully realize benefits as approvals need to be socialized and payment rates negotiated. Growth is currently driven more by existing users adopting more thoroughly than by new program starts from coverage wins.

“But the magnitude of it is at a point yet where it's still difficult for us to actually put a number to or quantify it. And it goes back to prior comments we made is that we know these events are not light switches.”

asked by Michael Kratky · answered by Michael Dale

What should be expected from the prostate program data in H2, specifically key endpoints and whether it applies only to radical prostatectomy or all prostatectomy surgeries?

The initial data will be from robotic radical prostatectomies on over 100 patients across 10+ sites, with about half having 6+ months follow-up. Endpoints include safety, reproducibility, and outcomes measured by erectile function, time to restoration, quality of function, and incontinence. Trends are positive, and a detailed update is expected in Q4, with physicians involved in the Q3 earnings call. The program focuses on mitigating consequences of existing injuries with minimal added risk.

“We're looking at both safety, reproducibility and the outcomes as measured by erectile function, time to restoration of function, quality of function and then the same with regards to incontinence. So in third quarter what we're still in the process of planning is the actual structure of our report, but we will have physicians involved who are key implanters who we'll invite so that you can speak to them directly.”

asked by Anthony Petrone · answered by Michael Dale

What inning is the Breast business in? What is the total program opportunity, surgeon count, rep needs, and major bottlenecks?

The Breast business is in very early innings. There are about 1,200 potential sites to service, with current active programs representing only a small portion. Patient and surgeon awareness is growing, with physicians feeling the need to offer breast resensation. The main bottleneck is the vast undertreated market and the need to continue educating patients and surgeons.

“We're still in very early innings. It's just very important to appreciate. So the total number of sites to service is about 1,200. Now to whether all 1,200 someday will be developed, that's difficult to say. But the long and short of it is that the sites that are currently up represent only a small number of the potential market development opportunity that exists.”

asked by Frank Takkinen · answered by Michael Dale